Back to results
US 2020/0270215 A1Published application
Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
AssigneeSignal Pharmaceuticals, LLC
InventorsHon-Wah MAN, Mohit Atul KOTHARE
Life of this patent
Estimating the term…
Abstract
Provided herein are isotopologues of Compound A, which are enriched with isotopes such as, for example, deuterium. Pharmaceutical compositions comprising the isotope-enriched compounds, and methods of using such compounds are also provided.
Claims7
A method for treating interstitial pulmonary fibrosis, comprising administering to a subject having interstitial pulmonary fibrosis an effective amount of a compound having the following structure:
- or a pharmaceutically acceptable salt, stereoisomer or solvate thereof,
- wherein one or more of Y1, Y2, Y3, Y4, Y5, Y6, Y7, Y8, Y9, Y10, Y11, Y12, Y13, Y14, Y15, Y16, Y17, Y18, Y19, Y20, Y21, and Y22 is a hydrogen that is isotopically enriched with deuterium, and the others of Y1, y2, Y3, Y4, Y5, Y6, Y7, Y8, Y9, Y10, Y11, Y12, Y13, Y14, Y15, Y16, Y16, Y18, Y19, Y20, Y21, and Y22 are non-enriched hydrogen atoms.
Dependencies are inferred from the claim text.